Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Microsoft Corporation. Read 's Market Analysis on Investing.com ...

STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

WEIGHT loss jabs could prevent a medication taken by millions of women from working – and increase patients’ risk of cancer. The British Menopause Society said the jabs could cause ...

Economists around the world are expecting muted U.S. economic growth in the coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...